Angeles Wealth Management LLC Boosts Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Angeles Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,943 shares of the medical research company’s stock after buying an additional 22 shares during the period. Angeles Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $2,051,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. AMF Tjanstepension AB purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $42,409,000. Valeo Financial Advisors LLC boosted its stake in Thermo Fisher Scientific by 4.8% during the third quarter. Valeo Financial Advisors LLC now owns 4,348 shares of the medical research company’s stock valued at $2,690,000 after buying an additional 198 shares during the last quarter. Lion Street Advisors LLC bought a new stake in Thermo Fisher Scientific in the 3rd quarter worth approximately $231,000. Octavia Wealth Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 17.1% during the 3rd quarter. Octavia Wealth Advisors LLC now owns 425 shares of the medical research company’s stock valued at $263,000 after acquiring an additional 62 shares during the last quarter. Finally, Perfromance Wealth Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the third quarter valued at $202,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TMO. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research note on Friday, January 10th. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Redburn Atlantic assumed coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 price objective for the company. Raymond James reissued an “outperform” rating and set a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Finally, UBS Group lifted their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $658.00.

Thermo Fisher Scientific Trading Down 0.2 %

Shares of NYSE TMO opened at $571.44 on Monday. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $547.34 and a two-hundred day simple moving average of $572.26. The firm has a market cap of $218.58 billion, a PE ratio of 34.57, a price-to-earnings-growth ratio of 3.18 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has initiated a stock buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In other news, CFO Stephen Williamson sold 9,825 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares in the company, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now directly owns 16,363 shares of the company’s stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,125 shares of company stock worth $11,231,699 over the last 90 days. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.